Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

被引:293
作者
Yang, YL
Ludwig, RL
Jensen, JP
Pierre, SA
Medaglia, MV
Davydov, IV
Safiran, YJ
Oberoi, P
Kenten, JH
Phillips, AC
Weissman, AM
Vousden, KH
机构
[1] NCI, Lab Prot Dynam & Signaling, Canc Res Ctr, NIH, Frederick, MD 21702 USA
[2] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[3] MesoScale Diagnost LLC, MesoScale Discovery, Gaithersburg, MD 20877 USA
[4] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA
关键词
D O I
10.1016/j.ccr.2005.04.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p53 tumor suppressor protein is regulated by its interaction with Ill which serves as a ubiquitin ligase (E3) to target p53 for degradation. We have identified a family of small molecules (HL198) that inhibits HDM2's E3 activity. These compounds show some specificity for HDM2 in vitro, although at higher concentrations effects on unrelated RING and HECT domain E3s are detectable, which could be due, at least in part, to effects on E2-ubiquitin thiol-ester levels. In cells, the compounds allow the stabilization of p53 and HDM2 and activation of p53-dependent transcription and apoptosis, although other p53-independent toxicity was also observed.
引用
收藏
页码:547 / 559
页数:13
相关论文
共 65 条
[1]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[2]   Stress signals utilize multiple pathways to stabilize p53 [J].
Ashcroft, M ;
Taya, Y ;
Vousden, KH .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (09) :3224-3233
[3]   Induction of p57KIP2 expression by p73β [J].
Bálint, É ;
Phillips, AC ;
Kozlov, S ;
Stewart, CL ;
Vousden, KH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :3529-3534
[4]  
Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001
[5]   Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation [J].
Bloom, J ;
Amador, V ;
Bartolini, F ;
DeMartino, G ;
Pagano, M .
CELL, 2003, 115 (01) :71-82
[6]   REGULATION OF TRANSCRIPTION FUNCTIONS OF THE P53 TUMOR-SUPPRESSOR BY THE MDM-2 ONCOGENE [J].
CHEN, JD ;
LIN, JY ;
LEVINE, AJ .
MOLECULAR MEDICINE, 1995, 1 (02) :142-152
[7]   Activation of p53 by oxidative stress involves platelet-derived growth factor-β receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation [J].
Chen, K ;
Albano, A ;
Ho, A ;
Keaney, JF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (41) :39527-39533
[8]   SIGNAL-INDUCED SITE-SPECIFIC PHOSPHORYLATION TARGETS I-KAPPA-B-ALPHA TO THE UBIQUITIN-PROTEASOME PATHWAY [J].
CHEN, ZJ ;
HAGLER, J ;
PALOMBELLA, VJ ;
MELANDRI, F ;
SCHERER, D ;
BALLARD, D ;
MANIATIS, T .
GENES & DEVELOPMENT, 1995, 9 (13) :1586-1597
[9]   Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].
Chène, P .
NATURE REVIEWS CANCER, 2003, 3 (02) :102-109
[10]   p53's believe it or not: Lessons on transcription-independent death [J].
Chipuk, JE ;
Green, DR .
JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (05) :355-361